Adaptive Biotech Q4 revenue $47.5M; MRD revenue up 31% YoY; FY2025 MRD guidance $175-185M

Adaptive Biotechnologies Corp

2024-FY EPS reported -$1.08 revenue$178,957,000

Q4 total revenue $47.5M (+4% YoY); full year $179.0M (+5%). MRD revenue $40.1M (+31% Q4, +42% FY).
clonoSEQ test volume Q4 20,945 tests (+34% YoY); full year 76,105 tests (+35%).
Net loss Q4 $33.7M vs $69.5M a year ago; FY net loss $159.6M vs $225.3M. Adjusted EBITDA loss Q4 $16.4M vs $24.7M.
FY2025 guidance: MRD revenue $175-185M; total operating expenses $340-350M; cash burn $60-70M.
FDA ODAC unanimously voted to support MRD as primary endpoint for accelerated approval in multiple myeloma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.